FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication...Read more
Data to be featured in Presidential Symposium at ESMO Signatera™ changes the paradigm by expanding the adjuvant decision window, with up to 7 tests in the first year post-surgery, enabling effective initiation of treatment only after a positive test result, and allowing patients with persistently negative results to avoid unnecessary treatment AUSTIN, Texas / Oct 20, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader...Read more
Study finds significantly lower rates of provider-initiated exome reanalysis among diverse racial, ethnic, and ancestral groups highlighting the importance of proactive reanalysis offerings like Ambry’s Patient for Life™ program ALISO VIEJO, Calif. / Oct 20, 2025 / Business Wire / Ambry Genetics, a leader in genetic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced the publication of a peer-reviewed...Read more
X-Chem’s DNA-encoded library complements Charles River’s discovery expertise to accelerate hit identification WILMINGTON, Mass. / Oct 20, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE:CRL) today announced a strategic collaboration with X-Chem, Inc., the pioneer in DNA-encoded library (DEL) technology and a data-driven drug discovery company, to enhance its hit identification (Hit ID) capabilities and...Read more
Epioxa Provides the Ophthalmic Community and Patients with the First and Only FDA-Approved, Incision-Free, Topical Drug Therapy for Keratoconus Epioxa Represents a Novel, Groundbreaking Therapy for Patients Afflicted by This Sight-Threatening Rare Disease Epioxa Expected to Be Commercially Available in Q1 2026 ALISO VIEJO, Calif. / Oct 20, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and...Read more
MENLO PARK, Calif., Oct. 20, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of approximately $325.0 million, before deducting placement agents' fees and other expenses. The private placement included the...Read more
One-Third of Participants Initially Believed to Have a False-Positive Result Were Later Diagnosed With Cancer During Follow Up Updated Positive Predictive Value of Galleri in This Symptomatic Population was 84.2% Galleri Accurately Predicted the Location of the Cancer in Almost All Cases Initially Considered as False Positives, Reinforcing the Value of Galleri's CSO Capability MENLO PARK, Calif. and OXFORD, United Kingdom,...Read more
LAKE FOREST, Calif. / Oct 20, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales results for the third quarter ended September 26, 2025. STAAR is announcing its preliminary net sales results in advance of its quarterly earnings announcement to provide all stockholders with...Read more
EL MONTE, Calif. / Oct 20, 2025 / Business Wire / Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced preliminary clinical data as of September 25, 2025, the preliminary data cutoff from its ongoing phase 2 clinical trial investigating FID-007 in combination with cetuximab in ≤ 2nd line...Read more
Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-α-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on study Initial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3,...Read more
Industry Veteran Steve La Neve Named Chief Executive Officer Suzanne Winter to Retire as President and CEO Company Appoints Steven F. Mayer as Transformation Board Sponsor Chan W. Galbato Nominated to Board of Directors MADISON, Wis., Oct. 20, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today announced it is engaging in a significant organizational, strategic, and operational transformation. To accelerate this...Read more
EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU Lyon, France – October 20, 2025 – EDAP TMS SA (Nasdaq: EDAP) (“EDAP” or the “Company”), a global leader in robotic, energy-based therapeutic technologies, today announced that it has entered into a €36 million multi-tranche credit facility (the “Credit Facility”) with the European Investment Bank (the...Read more
Visit the CyPath® Lung team at Booth #2242 October 19-22 SAN ANTONIO / Oct 20, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced it will present research at CHEST 2025, the annual meeting of the American College of Chest Physicians. The study supports the methods used to collect and transport...Read more
Conference Call October 20, 8:45am EST QUEENSBURY, N.Y. / Oct 18, 2025 / Business Wire / Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today provided preliminary revenue and financial results for the quarter ended September 30, 2025, and updated 2025 full-year revenue guidance. Preliminary Third Quarter Financial Results (unaudited) Total...Read more
Conference Call October 20, 8:45am EST QUEENSBURY, N.Y. / Oct 18, 2025 / Business Wire / Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the results of the CHOPIN randomized Phase 2 clinical trial (CHOPIN Trial) presented by Principal Investigator and Lead Author Professor Ellen Kapiteijn, MD, from Leiden University Medical...Read more
Acquisition to expand the neuromodulation offerings for people living with chronic pain MARLBOROUGH, Mass., Oct. 17, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Nalu Medical, Inc., a privately held medical technology company focused on developing and commercializing innovative and minimally invasive solutions for patients with chronic...Read more
Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelines PALM SPRINGS, CALIFORNIA / ACCESS Newswire / October 17, 2025 / Desert Oasis Healthcare (DOHC) is proud to announce a partnership with RadNet, Inc. (locally known as Desert Advanced Imaging) to offer Enhanced Breast Cancer Detection (EBCD) and improve outcomes for women across the...Read more
More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population MENLO PARK, Calif., Oct. 17, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when...Read more
MENLO PARK, Calif., Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced that two Medicare Administrative Contractors (MACs), Novitas Solutions, Inc. (Novitas) and First Coast Service Options, Inc. (FCSO),...Read more
WALTHAM, Mass. / Oct 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost...Read more
CHICAGO / Oct 16, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugates (ADC) cancer treatments. The collaboration aims to...Read more
Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea With Possible Expansion to Japan and Singapore Samsung Electronics and GRAIL Will Also Explore Potential Strategic and Operational Collaborations SEOUL, Korea and MENLO PARK, Calif., Oct. 16, 2025 /PRNewswire/ -- Samsung C&T...Read more
FDA-approved MTS™ DAT Card and advanced ORTHO VISION™ Platform highlight the company's continued leadership in transfusion medicine SAN DIEGO, Oct. 16, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a global leader of in vitro diagnostics, will highlight its ongoing commitment to transfusion medicine excellence at the Association for the Advancement of Blood & Biotherapies (AABB) 2025 Annual Meeting. The...Read more
First U.S. Based Medical Meeting Presence Post-FDA Clearance Will Allow the Company to Commercially Engage Future Potential Users of the LIBERTY® System Company Completes the Recruitment of its Commercial Leadership Team as it Remains On Track to Commence the Launch of The LIBERTY® SystemDuring Q4 of This Year HINGHAM, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of...Read more
Board Chairman Cary Vance appointed Interim CEO Board member Jan Stern Reed appointed Lead Independent Director Third quarter 2025 preliminary revenue expected to be approximately $17 million VALENCIA, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical”, or the “Company”), a leading therapeutic acute wound care company, today announced that the Board of Directors has named...Read more
APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify novel biomarkers that enable earlier detection and more precise...Read more
Will Showcase Latest Fertility Solutions SAN ANTONIO, Texas, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, is pleased to announce that it will exhibit at the American Society for Reproductive Medicine (ASRM) 2025 Scientific Congress & Expo, which will take place October...Read more
New device has the potential to help empower decentralized PCR testing in nearly 30,000 primary health centers across India, advancing efforts to improve availability of life-saving TB diagnostics SALT LAKE CITY, Oct. 16, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced...Read more
U.S. award protects AI-built platform and adds to growing international patent portfolio SAN ANTONIO, Texas / Oct 16, 2025 / Business Wire / bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company’s commercially available test for early-stage lung cancer, today announced it has received a notification of allowance from the United States...Read more
Odyssey Medical Devices, Inc., a subsidiary of Odyssey Health Inc., to acquire exclusive global marketing and distribution rights for the BreastCheck® LAS VEGAS, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTCQB: ODYY), a medical device company with a focus in life-saving medical solutions today announced that the company has signed a sub-licensing agreement for exclusive, worldwide rights to the BreastCheck®, a...Read more
Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors Relationship Marks a Key Milestone in Biomerica’s Commercialization Strategy IRVINE, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global biomedical company, announced today a marketing services arrangement with Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of...Read more
THE WOODLANDS, TX, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it will participate at the 2025 Maxim Growth Summit, taking place October 22-23, 2025 in New York, NY. This prestigious event brings together industry leaders, innovators, and premier institutions to explore the...Read more
TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it will be presenting at the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub on Wednesday, October 22, 2025...Read more
Third-quarter reported sales growth of 6.9 percent; organic sales growth of 5.5 percent or 7.5 percent excluding COVID-19 testing-related sales1 Third-quarter GAAP diluted EPS of $0.94; adjusted diluted EPS of $1.30 Reported operating margin of 18.1 percent of sales; adjusted operating margin of 23.0 percent, which reflects a 40 basis point increase ABBOTT PARK, Ill., Oct. 15, 2025 /PRNewswire/ -- Abbott (NYSE: ABT)...Read more
CHICAGO / Oct 15, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that six abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025, taking place October 17–21 in Berlin, Germany. “We’re sharing research at ESMO Congress 2025, including two oral presentations, that highlight the growing...Read more
At ASHG, an early access customer from the London Health Sciences Center Research Institute will demonstrate the power of the 5-base genome for accelerating resolution of rare disease cases Proprietary 5-base chemistry and novel DRAGEN algorithms enable dual-omic inquiry, providing researchers with new tool for precision medicine breakthroughs SAN DIEGO, Oct. 15, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced...Read more
15 abstracts spanning advancements in early detection of recurrence, tumor profiling, and therapy response monitoring Presentations highlight the power of Guardant Health’s blood-based assays to reduce treatment burden and improve disease monitoring across multiple cancer types PALO ALTO, Calif. / Oct 15, 2025 / Business Wire / Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that new data from...Read more
Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders. Asset acquisition is projected to add approximately $6 million to $8 million of revenue in 2026 in a key gastroenterology market that leverages Merit’s existing commercial footprint. SOUTH JORDAN, Utah, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Merit...Read more
BAAR, Switzerland / Oct 15, 2025 / Business Wire / Novocure (NASDAQ: NVCR) announced today that it will present data at two upcoming oncology congresses, the 2025 European Association of Neuro-Oncology (EANO) Meeting, being held October 16-19 in Prague, Czech Republic, and the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21 in Berlin, Germany. At the EANO 2025 Meeting, Novocure will present pre-clinical...Read more
BURLINGTON, Mass., Oct. 15, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Wednesday, December 10, 2025, at the Company's biorepository facility in Indianapolis, Indiana. This event will provide invited investors and analysts with a unique opportunity to gain an in-depth understanding of Azenta's operations, innovations, and strategic initiatives. Morning Facility Tour The day will...Read more
ST. LOUIS, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained CE Mark in Europe and submitted a 510(k) application to the FDA in the US for the Synchrony™ system. Synchrony is designed to digitize and modernize the interventional cath lab. Synchrony’s slim and stunning 55” 4K ultra-high-definition...Read more
MINNEAPOLIS and BRISBANE, Australia, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, announced today it has received regulatory clearance from the Danish Medicines Agency to initiate the DurAVR® Transcatheter Heart...Read more
Owlet expands its global footprint, entering one of the world’s most promising digital health markets, with CDSCO-approved technology. LEHI, Utah / Oct 15, 2025 / Business Wire / Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today announces that the Central Drugs Standard Control Organization (CDSCO) approved Dream Sock® for distribution. This marks a significant milestone for the Company...Read more
GUILFORD, Conn. / Oct 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced preliminary, unaudited financial results for the third quarter ended September 30, 2025. “In the third quarter, we saw strong market excitement and demand for our next generation...Read more
GUILFORD, Conn. / Oct 15, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR) (“Hyperfine” or the “Company”) today announced that it has commenced an underwritten public offering of its Class A common stock or, in lieu of Class A common stock to certain investors, pre-funded warrants to purchase Class A common stock. All securities to be sold in the offering will be sold by Hyperfine. In addition, Hyperfine intends to grant the...Read more
One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presented LOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois. Biodesix will be presenting data from an interim analysis...Read more
Reported Improved Gross Margin from Contribution from Higher-Margin Product Mix Operating Expenses Continued to Decline Compared to the First Quarter of the Prior Fiscal Year, Reflecting the Company’s Ongoing Focus on Cost Reduction and Operational Efficiency Earnings per Share $0.00, Compared to a Net Loss of $0.08 per Share in the First Quarter of the Prior Fiscal Year. IRVINE, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica,...Read more
PORTAGE, Mich. / Oct 14, 2025 / Business Wire / Stryker (NYSE:SYK), a global leader in medical technologies, will showcase new additions to its trauma offerings at the Orthopaedic Trauma Association (OTA) Annual Meeting, October 15–18, in Phoenix, Ariz. (booth #601). The company will highlight upcoming expansions to its nailing and plating platforms. For more than 80 years, Stryker has collaborated with surgeons to help design their...Read more
AUDUBON, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, has announced the launch of the ANTHEM™ Elbow Fracture System, a fully comprehensive plating portfolio designed to address a wide spectrum of elbow fractures. The ANTHEM™ Elbow Fracture System is designed to offer surgeons anatomically contoured plates to treat a variety of fractures, regardless of severity...Read more
ALISO VIEJO, Calif. / Oct 14, 2025 / Business Wire / Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held October 18-20, 2025, in Orlando,...Read more
NEW YORK / Oct 14, 2025 / Business Wire / Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, noted the publication of “The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech” in the Aesthetic Surgery Journal. The study showed a very low rate of complications,...Read more
FORT MYERS, Fla. / Oct 14, 2025 / Business Wire / NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional therapy trials in progress, to showcase how its molecular residual disease (MRD) assay may benefit pharmaceutical partners at the European Society for Medical Oncology (ESMO) Congress 2025,...Read more
The Foresight® Carrier Screen includes all conditions recommended by the American College of Medical Genetics and Genomics recommendations SALT LAKE CITY, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced it has added two genes, F8 and FXN, to the Foresight® Carrier Screen Universal Plus Panel. “At Myriad Genetics, we carefully...Read more
New SPRQ-Nx chemistry designed to deliver the most complete view of the genome for less than $300 at scale MENLO PARK, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced innovations to its Revio and Vega platforms designed to lower sequencing costs, add new multiomic capabilities, and expand support for regulated research environments. The...Read more
Presentation on Tuesday, October 21st at 11:00 AM PT Lafayette, Louisiana--(Newsfile Corp. - October 14, 2025) - Viemed Healthcare, Inc. (NASDAQ: VMD), a national leader of in-home, technology-enabled post-acute respiratory care, announced today that it will be presenting at the 19th annual Main Event on Tuesday, October 21st at 11:00 AM PT at the Hotel del Coronado in San Diego, California. Trae Fitzgerald, Chief Financial Officer...Read more
The Experienced MedTech Logistics Provider Will Help Ensure Effective and Efficient Inventory Management and Customer Support The Company is on Track to Commence the Launch of LIBERTY® during Q4 This Year HINGHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer and distributer of the innovative LIBERTY® Endovascular Robotic System, has partnered with a U.S. based third-party logistics...Read more
Calgary, Alberta – TheNewswire - October 14, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it is holding a webinar to discuss the one-month patient results for its initial Group 1 patients that received the Ocumetics Accommodating Intraocular Lens (the “Ocumetics Lens”). Webinar details are as...Read more
ENGLEWOOD, Colo., Oct. 14, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the appointment of Bret Wise to its Board of Directors. Mr. Wise will also serve as Chair of the Audit Committee. "Bret Wise is a great addition to our Board of...Read more
GAITHERSBURG, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, will present at the LD Micro Main Event XIX Conference in San Diego on Tuesday, October 21, 2025, at 1:00 p.m. PT (4:00 p.m. ET). LD Micro Main Event XIX ConferencePresentation Date: Tuesday, October 21,...Read more
TORONTO and DALLAS, Oct. 14, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company is pleased to announce that its CEO, Adrian Mendes, will present an update on the Company's business at the Small Cap Growth Virtual Investor Conference ("VIC") on Thursday, October 16, 2025 at 1:00 p.m. Eastern Time. The VIC is geared to a global...Read more
Toronto, Ontario, October 14, 2025 – TheNewswire - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Corporation”, TSXV:VPT) announces the issuance of an additional $297,000 of unsecured convertible debenture units (“Units”) of its non-brokered private placement (the “Offering”) (see August 26, 2025, September 3, 2025 and October 3, 2025 press releases), subject to TSXV Venture Exchange (“Exchange”) acceptance. Along with the issuance of...Read more
First English-language case study shows resolution of lesions with 308-nm Excimer laser in rare mycosis fungoides (MF) subtype, poikilodermatous mycosis fungiodes (pMF), underscoring the Company’s XTRAC capability to address the condition HORSHAM, Pa., Oct. 14, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and...Read more
Appoints Shawn Matthews, CEO of DNA Holdings Venture, Inc., and Former CEO of Cantor Fitzgerald, to its Board of Directors Names Thomas McLaughlin and Sara Turken, JD, as Chief Investment Officer and General Counsel, respectively PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and the first Strategic Compute Reserve leveraging the Aethir ecosystem to...Read more
AUSTIN, Texas / Oct 13, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will host a conference call and webcast on Thursday, Oct. 23, at 5:00 a.m. PT (8:00 a.m. ET) to discuss data in muscle-invasive bladder cancer that will be presented at the European Society for Medical Oncology (ESMO) Congress. This includes results from the randomized phase 3...Read more
Headlines: Xevo™ CDMS facilitates direct, accurate mass detection for the largest, most heterogeneous biomolecules.1 Enables accurate analysis of protein complexes, nucleic acids, and gene delivery vehicles, including distinguishing between empty, partial, full, and overfull viral vector capsids in less than 10 minutes per sample.2 Decreases sample volumes by 100 times vs. current methods for assessing cells and nucleic...Read more
30-day Data from the AMDS PERSEVERE Trial Demonstrates Visceral Malperfusion Resolution in 83%, and Renal Malperfusion Resolution in 74% of Affected Subjects Post-AMDS Implantation Real-World Data from the AMDS PROTECT Trial Validate Statistically Significant Positive Outcomes Demonstrated by the PERSEVERE and DARTS trials ATLANTA, Oct. 13, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery...Read more
More than 1,000 Korean genomes to be sequenced for global reference standards, advancing disease research and precision medicine MENLO PARK, Calif. and SEOUL, South Korea, Oct. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that its HiFi sequencing technology has been selected as the primary platform for the Korean Pangenome Reference...Read more
ST. LOUIS and MARLBOROUGH, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, and CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac arrhythmias, today announced they have entered into a Collaboration Agreement to advance robotic Pulsed Field Ablation (PFA) technology towards...Read more
Initiated Nationwide Commercial Launch of AYON in September The Company is Hosting a Virtual Key Opinion Leader Event to Discuss the Commercial Launch of AYON on October 14, 2025 CLEARWATER, Fla., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ: APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion® and the AYON...Read more
UniHA approves framework agreement covering over 1,500 French public hospitals, facilitating the purchase of Swoop® AI-powered portable MRI systems over three years GUILFORD, Conn. / Oct 13, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that its...Read more
FDA's marketing authorization for ProSense® for low-risk breast cancer received following the TME Fall Summit—Marketing authorization expected to further drive commercial traction based on the high level of interest received at the roundtable event CAESAREA, Israel, Oct. 13, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation...Read more
Company Also Intends to Appoint Jeff Dorman to Digital Asset Advisory Board ANN ARBOR, Mich. / Oct 13, 2025 / Business Wire / ENDRA Life Sciences Inc. (Nasdaq: NDRA) (“ENDRA” or the “Company”), a pioneer in imaging technologies for the early detection and monitoring of metabolic dysfunction associated liver disease (“MASLD”) and metabolic dysfunction associated steatohepatitis (“MASH”), today announced an aggregate of $4.9 million in...Read more
Six oral presentations highlight Signatera’s expanding role across solid tumors, including definitive predictive data in adjuvant bladder cancer AUSTIN, Texas / Oct 12, 2025 / Business Wire / Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October...Read more
MINNEAPOLIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today published Inspire V clinical outcomes data from its Singapore clinical study as well as the Company’s limited market release in the United States including single...Read more
Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System HAYWARD, Calif. / Oct 10, 2025 / Business Wire / Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical study results from the nPulse™ Cardiac Surgical System...Read more
PALM BEACH GARDENS, Fla., Oct. 10, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (“ZimVie”) (Nasdaq: ZIMV) today announced that at the special meeting of ZimVie stockholders held on October 10, 2025, the ZimVie stockholders voted to approve the acquisition of ZimVie by an affiliate of ARCHIMED (the “Merger”) pursuant to the terms and conditions of the Agreement and Plan of Merger, dated as of July 20, 2025 (the “Merger Agreement”). The parties...Read more
Industry leader brings 40 years of executive and board experience across the global medical technology sector GAITHERSBURG, Md., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, announced the appointment of Guido J. Neels to the Company’s Board of Directors. Mr. Neels will also serve as a member of the audit committee of the Board. In...Read more
Toronto, Ontario--(Newsfile Corp. - October 10, 2025) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma" or the "Company"), a developer and investment partner in advanced diagnostic and medical device technologies, is pleased to announce the appointment of Michael Raimondo, a 30-year veteran in sales and operations in the healthcare industry to its Board of Directors. Michael was part of Therma's advisory Board,...Read more
ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series F warrants to purchase up to...Read more
FRANKLIN LAKES, N.J., Oct. 9, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in the XTRACT™ Registry, a prospective, multi-center, single-arm, post-market registry study designed to evaluate the real-world performance of the Rotarex™ Catheter System in the treatment of patients with peripheral artery disease (PAD)...Read more
CHICAGO / Oct 09, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to provide testing and contract research organization (CRO) services in support of the agency’s ADAPT (Advanced Analysis for...Read more
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that the American Medical Association (AMA) CPT Editorial Panel has established a Category I Current Procedural Terminology (CPT) code for procedures involving its CARTIHEAL AGILI-C Cartilage Repair Implant, effective January 1, 2027. The new CPT code recognizes the clinical significance and growing adoption of the CARTIHEAL Implant, a...Read more
Company to host conference call today, October 9th, 2025, to discuss the financial results and updated outlook WARSAW, Ind., Oct. 09, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced preliminary unaudited financial highlights for the third quarter ended September 30, 2025, and revised 2025...Read more
VANCOUVER, BC / ACCESS Newswire / October 9, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT) (OTCQB:BNXTF) (FSE:BXT), a bioscience innovator specializing in next-generation drug delivery technologies, today announced that it has completed a Track One priority patent filing with the U.S. Patent and Trademark Office (USPTO) for its proprietary sublingual thin-film cladribine formulation (BNT23001), designed for the...Read more
MALVERN, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio”) (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Betty Jo Rocchio, DNP, RN, CRNA, CENP, EBP-C, to its Board of Directors, and the departure of Lisa Colleran, who has stepped down following five years of service on the Board. Dr. Rocchio is a...Read more
HENDERSON, Nev., Oct. 9, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it is proposing to offer and sell, in an underwritten public offering, shares of its common stock and accompanying common stock purchase warrants. In addition, Volition intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the...Read more
$4 million upfront with up to additional $12 million of potential aggregate gross proceeds upon the exercise in full of warrants White Bear Lake, Minnesota--(Newsfile Corp. - October 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced...Read more
LANGHORNE, Pa., Oct. 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that Adam Levy, Chief Executive Officer, will present at the LD Micro Main Event XIX Conference being held at the Hotel Del Coronado in...Read more
SAN ANTONIO / Oct 09, 2025 / Business Wire / bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced it has closed the previously announced definitive agreements for the purchase and sale of 720,000 shares of common stock at a purchase price of $2.50 per share in a registered direct offering priced at-the-market under...Read more
Recognition highlights commercial potential of Telo's telomere-based MRD technology in the growing precision oncology market Toronto, Ontario--(Newsfile Corp. - October 9, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in the development of diagnostic and prognostic tests for human disease through its proprietary multi-factor analysis of telomeres, today announced that the American...Read more
| Company | Change | Last Trade |
|---|---|---|
| Medpace | 16.34 3.09 | $544.41 |
| GRAIL | 13.85 17.76 | $91.85 |
| Intuitive | 12.34 2.77 | $458.47 |
| Bio-Rad Laboratories | 11.88 3.83 | $321.90 |
| Waters | 8.59 2.57 | $343.18 |
| Insulet | 8.26 2.59 | $326.85 |
| Senseonics | 8.06 1,975.98 | $8.47 |
| IDEXX Laboratories | 8.01 1.26 | $643.41 |
| Mettler-Toledo | 7.98 0.59 | $1,357.26 |
| IQVIA | 7.50 3.67 | $212.05 |
| Natera | 6.91 3.80 | $188.60 |
| Stryker | 6.80 1.82 | $381.22 |
| Charles River Laboratories | 5.62 3.15 | $184.14 |
| Labcorp | 4.99 1.75 | $290.93 |
| Aethlon Medical | 4.95 910.68 | $5.49 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE